GNF-2 is an inhibitor of Abl kinase that exhibits anticancer chemotherapeutic, anti-resorptive, and anti-osteoporotic activities. GNF-2 shows potential benefit in the treatment of Philadelphia chromosome-positive acute myelogenous leukemia (ALL). In vitro, GNF-2 inhibits differentiation of osteoclasts, activity of NF-κB, and induction of c-Fos and NFATc1, resulting in caspase-mediated apoptosis. GNF-2 also inhibits resorption of mature osteoclasts and prevents phagocytosis in bone marrow-derived macrophages. In vivo, this compound decreases osteoclast numbers and prevents bone loss.